152 related articles for article (PubMed ID: 34197012)
21. Benefit and risk of adding rivaroxaban in patients with coronary artery disease: A systematic review and meta-analysis.
Xie C; Hang Y; Zhu J; Li C; Jiang B; Zhang Y; Miao L
Clin Cardiol; 2021 Jan; 44(1):20-26. PubMed ID: 33219708
[TBL] [Abstract][Full Text] [Related]
22. Livedoid vasculopathy: Clinical course and long-term outcome in Asian patients with a review of the literature.
Rujitharanawong C; Chularojanamontri L; Trakanwittayarak S; Pinkaew S; Nuttawong S
Dermatol Ther; 2021 Jan; 34(1):e14569. PubMed ID: 33219608
[TBL] [Abstract][Full Text] [Related]
23. Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary Syndrome.
Gibson CM; Levitan B; Gibson WJ; Yee MK; Murphy SA; Yuan Z; Chakrabarti AK; Lee M; Braunwald E
J Am Coll Cardiol; 2018 Jul; 72(2):129-136. PubMed ID: 29976285
[TBL] [Abstract][Full Text] [Related]
24. Livedoid vasculopathy in Koreans: clinical features and response to rivaroxaban treatment.
Lee JS; Cho S
J Eur Acad Dermatol Venereol; 2020 Apr; 34(4):e176-e178. PubMed ID: 31793049
[No Abstract] [Full Text] [Related]
25. Prevention of livedoid vasculopathy recurrence by prolonged administration of rivaroxaban.
Drerup C; Goerge T
J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):e532. PubMed ID: 28609556
[No Abstract] [Full Text] [Related]
26. Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate.
Sheikh-Taha M
Intern Emerg Med; 2019 Mar; 14(2):265-269. PubMed ID: 30414056
[TBL] [Abstract][Full Text] [Related]
27. Treatment of Livedoid Vasculopathy With Rivaroxaban: A Potential Use of New Oral Anticoagulants for Dermatologists.
Jiménez-Gallo D; Villegas-Romero I; Rodríguez-Mateos ME; Linares-Barrios M
Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):278-281. PubMed ID: 29074145
[No Abstract] [Full Text] [Related]
28. Analysis of the German DRG data for livedoid vasculopathy and calciphylaxis.
Renner R; Dissemond J; Goerge T; Hoff N; Kröger K; Erfurt-Berge C
J Eur Acad Dermatol Venereol; 2017 Nov; 31(11):1884-1889. PubMed ID: 28252815
[TBL] [Abstract][Full Text] [Related]
29. Successful treatment of livedoid vasculopathy with rivaroxaban.
Evans JM; Jensen JD; Sami N
JAAD Case Rep; 2015 Nov; 1(6):340-1. PubMed ID: 27051773
[No Abstract] [Full Text] [Related]
30. Effectiveness and safety of rivaroxaban for the prevention of thrombosis following total hip or knee replacement: A systematic review and meta-analysis.
Liu J; Zhao J; Yan Y; Su J
Medicine (Baltimore); 2019 Mar; 98(9):e14539. PubMed ID: 30817570
[TBL] [Abstract][Full Text] [Related]
31. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S;
Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867
[TBL] [Abstract][Full Text] [Related]
32. Livedoid vasculopathy with underlying subcutaneous necrotizing venulitis in an asymptomatic hepatitis B virus carrier: is livedoid vasculopathy a true nonvasculitic disorder?
Ishibashi M; Miyamoto J; Nagasaka T; Chen KR
Am J Dermatopathol; 2009 May; 31(3):293-6. PubMed ID: 19384073
[TBL] [Abstract][Full Text] [Related]
33. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
[TBL] [Abstract][Full Text] [Related]
34. Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial.
Leef GC; Hellkamp AS; Patel MR; Becker RC; Berkowitz SD; Breithardt G; Halperin JL; Hankey GJ; Hacke W; Nessel CC; Singer DE; Fox KAA; Mahaffey KW; Piccini JP
J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28615214
[TBL] [Abstract][Full Text] [Related]
35. Rivaroxaban-induced hepatotoxicity: review of the literature and report of new cases.
Licata A; Puccia F; Lombardo V; Serruto A; Minissale MG; Morreale I; Giannitrapani L; Soresi M; Montalto G; Almasio PL
Eur J Gastroenterol Hepatol; 2018 Feb; 30(2):226-232. PubMed ID: 29120909
[TBL] [Abstract][Full Text] [Related]
36. Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial.
Yhim HY; Choi WI; Kim SH; Nam SH; Kim KH; Mun YC; Oh D; Hwang HG; Lee KW; Song EK; Kwon YS; Bang SM
Korean J Intern Med; 2019 Sep; 34(5):1125-1135. PubMed ID: 29788694
[TBL] [Abstract][Full Text] [Related]
37. Rivaroxaban: an oral factor Xa inhibitor.
Thomas TF; Ganetsky V; Spinler SA
Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
[TBL] [Abstract][Full Text] [Related]
38. Livedoid vasculopathy: long-term follow-up results following hyperbaric oxygen therapy.
Juan WH; Chan YS; Lee JC; Yang LC; Hong HS; Yang CH
Br J Dermatol; 2006 Feb; 154(2):251-5. PubMed ID: 16433793
[TBL] [Abstract][Full Text] [Related]
39. Dermoscopic features of livedoid vasculopathy.
Hu SC; Chen GS; Lin CL; Cheng YC; Lin YS
Medicine (Baltimore); 2017 Mar; 96(11):e6284. PubMed ID: 28296736
[TBL] [Abstract][Full Text] [Related]
40. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.
Gibson CM; Mega JL; Burton P; Goto S; Verheugt F; Bode C; Plotnikov A; Sun X; Cook-Bruns N; Braunwald E
Am Heart J; 2011 May; 161(5):815-821.e6. PubMed ID: 21570509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
